Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
Apogee Therapeutics, a clinical-stage biotech company specializing in novel biologics for inflammatory and immunology markets, has priced a $350 million underwritten public offering of 5 million shares at $70 each. The offering aims to strengthen the company's financial position to advance its pipeline, including its lead candidate Zumilokibart tar…